For the record - Oct. 8, 2007
Breast cancer: An article in the Oct. 1 Health section stated that the medication raloxifene, or Evista, may soon be approved for breast cancer prevention in high-risk women. In fact, Evista was approved Sept. 14 for prevention of breast cancer in high-risk post-menopausal women and post-menopausal women with osteoporosis.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
